Skip to content

ISICORT®/Zeqmelit

In the development of ISICORT®/Zeqmelit, a fast-soluble oral film containing the glucocorticoid dexamethasone, AcuCort has managed to combine the benefits of the well-proven substance and the user-friendly mouth film for quick availability and relief in emergency situations. The drug is the company’s first market-approved product.

The active anti-inflammatory substance dexamethasone belongs to the group of glucocorticoids which is a very well-known, well-proven and well-established group of drugs. Glucocorticoids have been used clinically since the 1960s and are prescribed for the treatment of many diseases. Thus, there is great knowledge among the medical profession and healthcare about glucocorticoids and experience from prescribing this group of drugs. Glucocorticoids suppress immune reactions and inflammatory processes. Dexamethasone is one of the more potent glucocorticoids, which means that even small amounts e.g., in an ISICORT®/Zeqmelit mouth film provide effective relief.

Intellectual property rights such as patent and trademark protection play a crucial role in AcuCort’s future commercial opportunities. The company has an active patent strategy that covers the important pharmaceutical markets. ISICORT®/Zeqmelit is protected by two patents. The patent protection covers both the oral film technology with steroids and the production process.

One mouth film corresponds to one dose

ISICORT®/Zeqmelit is a thin, quick-dissolving and user-friendly mouth film that melts on the tongue within 10 – 15 seconds. The patient does not need any water to use the product. The mouth film is found in a small and flexible package in the size of a business card. An acute and severe allergic reactions can occur suddenly and without warning. With ISICORT®/Zeqmelit, the patient can always have quick access to his or her medicine.

The mouth film concept is simple. One mouth film is a dose. This is simple, practical and safe for the patient and his family.

Indications and positioning

AcuCort’s drug is approved in Sweden under the brand name ISICORT® and in Denmark and Norway under the name Zeqmelit. The drug is approved for, among other things, the treatment of acute and severe allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with COVID-19 with breathing difficulties and need for oxygen therapy.

ISICORT®/Zeqmelit is a drug for emergency medication, a so-called “rescue product”, for persons who may be affected or belong to the risk group for acute and severe allergic reactions.

ISICORT positioning in the treatment of allergy
1 Grand View Research, Allergy therapeutics market analysis and segment forecasts to 2025